I
13.20
0.02 (0.15%)
| Previous Close | 13.18 |
| Open | 13.19 |
| Volume | 679,838 |
| Avg. Volume (3M) | 1,232,539 |
| Market Cap | 1,028,422,464 |
| Price / Earnings (Forward) | 5.70 |
| Price / Sales | 0.660 |
| Price / Book | 1.05 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | -1.78% |
| Operating Margin (TTM) | 8.23% |
| Diluted EPS (TTM) | -0.380 |
| Quarterly Revenue Growth (YOY) | 3.70% |
| Quarterly Earnings Growth (YOY) | -2.00% |
| Total Debt/Equity (MRQ) | 132.59% |
| Current Ratio (MRQ) | 1.21 |
| Operating Cash Flow (TTM) | 102.37 M |
| Levered Free Cash Flow (TTM) | 35.55 M |
| Return on Assets (TTM) | 2.66% |
| Return on Equity (TTM) | -1.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Integra LifeSciences Holdings C | Bearish | Bearish |
AIStockmoo Score
-0.3
| Analyst Consensus | -1.5 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -1.5 |
| Average | -0.30 |
|
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 14.23% |
| % Held by Institutions | 96.47% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Truist Securities, 13.64%) | Hold |
| Median | 13.50 (2.27%) | |
| Low | 12.00 (Citigroup, -9.09%) | Sell |
| Average | 13.50 (2.27%) | |
| Total | 1 Hold, 1 Sell | |
| Avg. Price @ Call | 14.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 15 Oct 2025 | 15.00 (13.64%) | Hold | 14.23 |
| Citigroup | 07 Oct 2025 | 12.00 (-9.09%) | Sell | 14.43 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SINGH HARVINDER | - | 13.34 | -3,281 | -43,769 |
| Aggregate Net Quantity | -3,281 | |||
| Aggregate Net Value ($) | -43,769 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.34 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SINGH HARVINDER | Officer | 12 Oct 2025 | Disposed (-) | 3,281 | 13.34 | 43,769 |
| SINGH HARVINDER | Officer | 12 Oct 2025 | Option execute | 11,965 | - | - |
| Date | Type | Details |
|---|---|---|
| 15 Oct 2025 | Announcement | Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025 |
| 08 Oct 2025 | Announcement | Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting |
| 22 Sep 2025 | Announcement | Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer |
| 29 Aug 2025 | Announcement | Integra LifeSciences Leadership to Present at Wells Fargo and Morgan Stanley Healthcare Investor Conferences |
| 31 Jul 2025 | Announcement | Integra LifeSciences Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |